Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.

IF 12.5 2区 医学 Q1 SURGERY
Chao Li, Gaohaer Kadeerhan, Tongtong Zhang, Zaiwuli Yeerjiang, Yikun Yang, Jun Meng, Dongwen Wang
{"title":"Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.","authors":"Chao Li, Gaohaer Kadeerhan, Tongtong Zhang, Zaiwuli Yeerjiang, Yikun Yang, Jun Meng, Dongwen Wang","doi":"10.1097/JS9.0000000000002183","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Pathologic complete response (pCR) is deemed to associate with event-free survival (EFS) and overall survival (OS), however, whether it is suitable to serve as a surrogate endpoint for long-term survival in clinical trials of neo-adjuvant treatment for resectable NSCLC trials is still controversy. We aim to evaluate the role of pCR and its viability as a surrogate endpoint for EFS and OS in NSCLC.</p><p><strong>Methods: </strong>To investigate the association of pCR and EFS and OS, we performed a meta-analysis involving randomized clinical trials that have reported complete information on pCR rates with hazard ratios (HRs) for EFS and OS. A standard meta-analysis was conducted to determine the relationship between pCR rates and EFS and OS. Additionally, weighted regression analysis was performed to assess the associations between log relative risk (RR) for pCR and log HRs for EFS and OS, with the coefficient of determination (R 2 ) being used to quantify the correlations. Furthermore, the surrogate threshold effect (STE) was also used to evaluate the minimum value of the RR for pCR necessary to confidently predict a non-null effect on HRs for EFS and OS.</p><p><strong>Results: </strong>The meta-analysis included 14 randomized clinical trials. The high pCR rate group had significant improvement of EFS (HR = 0.69, 95%CI 0.55-0.86) and OS (HR = 0.82, 95%CI 0.72-0.94). A strong association was found between log RR for pCR and log HR for EFS (R 2  = 0.76; 95%CI 0.48-1.00) and a moderate correlation between log RR for pCR and log HR for OS (R 2  = 0.54; 95%CI 0.04-1.00). The STEs for pCR were 4.534 and 10.278 for EFS and OS, respectively. In the subgroup analysis, similar results were only observed in a partial set of comparisons.</p><p><strong>Conclusions: </strong>A high pCR rate was associated with a long-term survival outcome. Strong association and moderate association were found between pCR and EFS, pCR and OS, respectively, which supports the application of pCR as a surrogate endpoint for long-term survival in RCTs for resectable NSCLC.</p>","PeriodicalId":14401,"journal":{"name":"International journal of surgery","volume":" ","pages":"2216-2226"},"PeriodicalIF":12.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JS9.0000000000002183","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Pathologic complete response (pCR) is deemed to associate with event-free survival (EFS) and overall survival (OS), however, whether it is suitable to serve as a surrogate endpoint for long-term survival in clinical trials of neo-adjuvant treatment for resectable NSCLC trials is still controversy. We aim to evaluate the role of pCR and its viability as a surrogate endpoint for EFS and OS in NSCLC.

Methods: To investigate the association of pCR and EFS and OS, we performed a meta-analysis involving randomized clinical trials that have reported complete information on pCR rates with hazard ratios (HRs) for EFS and OS. A standard meta-analysis was conducted to determine the relationship between pCR rates and EFS and OS. Additionally, weighted regression analysis was performed to assess the associations between log relative risk (RR) for pCR and log HRs for EFS and OS, with the coefficient of determination (R 2 ) being used to quantify the correlations. Furthermore, the surrogate threshold effect (STE) was also used to evaluate the minimum value of the RR for pCR necessary to confidently predict a non-null effect on HRs for EFS and OS.

Results: The meta-analysis included 14 randomized clinical trials. The high pCR rate group had significant improvement of EFS (HR = 0.69, 95%CI 0.55-0.86) and OS (HR = 0.82, 95%CI 0.72-0.94). A strong association was found between log RR for pCR and log HR for EFS (R 2  = 0.76; 95%CI 0.48-1.00) and a moderate correlation between log RR for pCR and log HR for OS (R 2  = 0.54; 95%CI 0.04-1.00). The STEs for pCR were 4.534 and 10.278 for EFS and OS, respectively. In the subgroup analysis, similar results were only observed in a partial set of comparisons.

Conclusions: A high pCR rate was associated with a long-term survival outcome. Strong association and moderate association were found between pCR and EFS, pCR and OS, respectively, which supports the application of pCR as a surrogate endpoint for long-term survival in RCTs for resectable NSCLC.

评估病理完全缓解作为非小细胞肺癌患者长期生存的替代终点:一项系统回顾和荟萃分析
目的:病理完全缓解(pCR)被认为与无事件生存期(EFS)和总生存期(OS)相关,但在可切除NSCLC试验的新辅助治疗临床试验中,它是否适合作为长期生存期的替代终点仍存在争议。为了研究pCR与EFS和OS的相关性,我们进行了一项荟萃分析,涉及随机临床试验,这些试验报告了EFS和OS的pCR率与风险比(hr)的完整信息。进行标准荟萃分析以确定pCR率与EFS和OS之间的关系。此外,进行加权回归分析以评估pCR的对数相对风险(RR)与EFS和OS的对数相对风险(hr)之间的相关性,并使用决定系数(R2)来量化相关性。此外,还使用替代阈值效应(STE)来评估pCR所需的最小RR值,以自信地预测EFS和OS对hr的非零效应。结果:meta分析纳入14项随机临床试验。高pCR率组患者EFS (HR = 0.690, 95%CI 0.552 ~ 0.862)和OS (HR = 0.820, 95%CI 0.715 ~ 0.940)均有显著改善。pCR的对数RR和EFS的对数HR之间存在很强的相关性(R2 = 0.76;95%CI 0.48-1.00), pCR的对数RR和OS的对数HR之间存在中度相关性(R2 = 0.54;95%可信区间0.04 - -1.00)。EFS和OS pCR的STEs分别为4.534和10.278。在亚组分析中,类似的结果仅在部分组比较中观察到。结论:高pCR率与长期生存结果相关。pCR与EFS、pCR与OS之间分别存在强相关性和中度相关性,这支持了pCR作为可切除非小细胞肺癌rct长期生存的替代终点的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
17.70
自引率
3.30%
发文量
0
审稿时长
6-12 weeks
期刊介绍: The International Journal of Surgery (IJS) has a broad scope, encompassing all surgical specialties. Its primary objective is to facilitate the exchange of crucial ideas and lines of thought between and across these specialties.By doing so, the journal aims to counter the growing trend of increasing sub-specialization, which can result in "tunnel-vision" and the isolation of significant surgical advancements within specific specialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信